VistaGen Therapeutics Inc (VTGN)

[MissionIR]

Archived Press Releases

September 14, 2011
VistaGen Therapeutics Provides Investor Update On Corporate Activities and Upcoming Initiatives
http://www.vistagen.com/?p=233

May 17, 2011
VistaGen Therapeutics and Excaliber Enterprises Announce Completion of Reverse Merger and $3.8 Million Financing
http://www.vistagen.com/?p=58

January 12, 2011
VistaGen Therapeutics and NuPotential Receives NIH Grant to Develop Safer Approaches for Producing Patient-specific Induced Pluripotent Stem Cells
http://www.vistagen.com/?p=72

December 22, 2010
VistaGen Therapeutics Announces Successful Completion of Initial Phase 1 Safety Study of AV-101 for Neuropathic Pain
http://www.vistagen.com/?p=150

August 20, 2009
VistaGen Appoints Industry Veteran Shawn Singh as Chief Executive Officer
http://www.vistagen.com/?p=152

January 15, 2009
VistaGen and Capsant Sign Strategic Stem Cell Technology Commercialization Agreement
http://www.vistagen.com/?p=154

December 18, 2008
VistaGen and WARF Sign License Agreement for Human Embryonic Stem Cell Technology
http://www.vistagen.com/?p=156

December 16, 2008
VistaGen Receives Significant Stem Cell Tools and Technologies Grant from California Institute for Regenerative Medicine
http://www.vistagen.com/?p=158

October 16, 2008
VistaGen Team Pinpoints Key Biochemical Pathways Involved in Generating ES cell-derived Heart Cells
http://www.vistagen.com/?p=160

June 17, 2008
New Broad Composition of Matter Patent Protects VistaGen’s ES Cell Applications
http://www.vistagen.com/?p=162

May 22, 2008
VistaGen Licenses Customized Stem Cell-Based Drug Discovery Assays to Sanwa, a Japanese Pharmaceutical Company
http://www.vistagen.com/?p=164

April 23, 2008
VistaGen Collaborates with Canadian, U.S., and British Researchers ToIsolate Earliest Embryonic Stem Cell-Derived Human Cardiac Cell
http://www.vistagen.com/?p=166

March 12, 2008
VistaGen Therapeutics Announces Broad Stem Cell R&D Alliance With Toronto’s University Health Network and The McEwen Centre For Regenerative Medicine
http://www.vistagen.com/?p=168

November 23, 2007
VistaGen Sees Promise for Stem Cell ‘Breakthrough’ to Accelerate Drug Discoveryand Development
http://www.vistagen.com/?p=170

November 12, 2007
VistaGen Publishes Preclinical Data Supporting the Therapeutic Potential of AV-101 for Parkinson’s Disease — Company’s Lead Compound Can Stimulate Dopaminergic Neuron Activity —
http://www.vistagen.com/?p=172

November 6, 2007
VistaGen Awarded $1.2 Million from NIH for Development of AV-101 for Neuropathic Pain, Parkinson’s Disease and Epilepsy
http://www.vistagen.com/?p=174

January 30, 2007
VistaGen’s AV-101 Drug Candidate Yields Positive Preclinical Data for Neuropathic Pain Applications– IND to be Submitted to FDA in 2007 —
http://www.vistagen.com/?p=176

December 21, 2006
VistaGen Therapeutics Announces 3 Significant Publications Supporting the Use of Embryonic Stem Cells for Drug Discovery and Development
http://www.vistagen.com/?p=178

December 7, 2006
VistaGen Therapeutics Announces Positive AV-101 Preclinical Data Suggesting Potential for Parkinson’s Disease
http://www.vistagen.com/?p=181

November 30, 2006
VistaGen Therapeutics and Sanwa Renew Embryonic Stem Cell Drug Discovery and Development Partnership Focused on New Diabetes Treatments
http://www.vistagen.com/?p=184

March 23, 2006
VistaGen Therapeutics and CATO BioVentures Sign Strategic Business Development Agreement for CNS Products
http://www.vistagen.com/?p=186

August 23, 2005
Lantos Affirms Support of Expanded Stem Cell Research–Applauds Commitmentby VistaGen Employees and Investors
http://www.vistagen.com/?p=188

August 11, 2005
VistaGen Therapeutics Secures Development Support for New Drug Candidate for Huntington’s Disease
http://www.vistagen.com/?p=190

July 12, 2005
VistaGen Therapeutics Awarded $197,000 NIH Grant for Expanded Preclinical Development of New Drug Candidate for Neuropathic Pain
http://www.vistagen.com/?p=192

May 24, 2005
VistaGen Therapeutics Awarded $3,700,000 NIH Drug Development Grant for Lead Epilepsy Drug Candidate
http://www.vistagen.com/?p=194